Skip to content

Where Did the Authors Work When They Conducted Their Clinical Pharmacology Studies?

Countries Where the Main Authors and Their Collaborators of Recently Published Clinical Pharmacology Studies Worked

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07115680
Enrollment
503
Registered
2025-08-11
Start date
2025-09-15
Completion date
2025-11-30
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scientific Collaboration in Clinical Pharmacology

Keywords

Clinical pharmacology, studies on humans, recently published

Brief summary

It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."

Detailed description

Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.

Interventions

OTHERhuman participants, data or material

Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies

Sponsors

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Articles on human participants, data or material. Original articles, short reports, research letters.

Exclusion criteria

* In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.

Design outcomes

Primary

MeasureTime frameDescription
countries where authors conducted their studyArticles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes firstThe country of the principal authors and of all collaborators will be registered following Nature Index 'share' concept

Countries

Spain

Contacts

PRINCIPAL_INVESTIGATORRafael Dal-Re, MD, PhD, MPH

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026